Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model.
Keliang Xie, Yonghao Yu, Zishen Zhang, Wenbo Liu, Yuping Pei, Lize Xiong, Lichao Hou, Guolin Wang · Shock (Augusta, Ga.) · 2010
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The researchers found that the beneficial effects of H₂ treatment on ZY-induced organ damage were associated with the decreased levels of oxidative product, increased activities of antioxidant enzyme, and reduced levels of early and late proinflammatory cytokines in serum and tissues. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. The researchers found that the beneficial effects of H₂ treatment on ZY-induced organ damage were associated with the decreased levels of oxidative product, increased activities of antioxidant enzyme, and reduced levels of early and late proinflammatory cytokines in serum and tissues.
What the Researchers Studied
The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
2% inhaled H₂ concentration; reported treatment duration: 60 min. The researchers found that the beneficial effects of H₂ treatment on ZY-induced organ damage were associated with the decreased levels of oxidative product, increased activities of antioxidant enzyme, and reduced levels of early and late proinflammatory cytokines in serum and tissues. The authors concluded that, this study provides evidence that H₂ treatment protects against multiple organ damages in ZY-induced generalized inflammation model, suggesting the potential use of H₂ as a therapeutic agent in the therapy of conditions associated with inflammation-related multiple organ dysfunction syndrome.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The study used a preclinical animal experiment. The reported hydrogen concentration was 2% inhaled H₂ concentration. The reported treatment duration was 60 min.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.